Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Intravenous amphotericin B, with or without flucytosine, is usually standard therapy for cryptococcal meningitis in patients with the acquired immunodeficiency syndrome (AIDS). Fluconazole, an oral triazole agent, represents a promising new approach to the treatment of cryptococcal disease. METHODS: In a randomized multicenter trial, we compared intravenous amphotericin B with oral fluconazole as primary therapy for AIDS-associated acute cryptococcal meningitis. Eligible patients, in all of whom the diagnosis had been confirmed by culture, were randomly assigned in a 2:1 ratio to receive either fluconazole (200 mg per day) or amphotericin B. Treatment was considered successful if the patient had had two consecutive negative cerebrospinal fluid cultures by the end of the 10-week treatment period. RESULTS: Of the 194 eligible patients, 131 received fluconazole and 63 received amphotericin B (mean daily dose, 0.4 mg per kilogram of body weight in patients with successful treatment and 0.5 mg per kilogram in patients with treatment failure; P = 0.34). Treatment was successful in 25 of the 63 amphotericin B recipients (40 percent; 95 percent confidence interval, 26 percent to 53 percent) and in 44 of the 131 fluconazole recipients (34 percent; 95 percent confidence interval, 25 percent to 42 percent) (P = 0.40). There was no significant difference between the groups in overall mortality due to cryptococcosis (amphotericin vs. fluconazole, 9 of 63 [14 percent] vs. 24 of 131 [18 percent]; P = 0.48); however, mortality during the first two weeks of therapy was higher in the fluconazole group (15 percent vs. 8 percent; P = 0.25). The median length of time to the first negative cerebrospinal fluid culture was 42 days (95 percent confidence interval, 28 to 71) in the amphotericin B group and 64 days (95 percent confidence interval, 53 to 67) in the fluconazole group (P = 0.25). Multivariate analyses identified abnormal mental status (lethargy, somnolence, or obtundation) as the most important predictive factor of a high risk of death during therapy (P less than 0.0001). CONCLUSIONS: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS. Single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure. The optimal therapy for patients at high risk remains to be determined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Snedecor, G. W., & Cochran, W. G. (1967) · Cited by 6,573
Levy, R. M., Bredesen, D. E., & Rosenblum, M. L. (1985) · Journal of Neurosurgery · doi:10.3171/jns.1985.62.4.0475 · Cited by 1,129
“Proving the null hypothesis” in clinical trials
Blackwelder, W. C. (1982) · Controlled Clinical Trials · doi:10.1016/0197-2456(82)90024-1 · Cited by 887
Bennett, J. E., Dismukes, W. E., Duma, R. J., Medoff, G., Sande, M. A., Gallis, H., Leonard, J., Fields, B. T., Bradshaw, M., Haywood, H., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197907193010303 · Cited by 863
Self-citationInfections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Cryptococcosis in the Acquired Immunodeficiency Syndrome
KOVACS, J. A., KOVACS, A. A., POLIS, M., WRIGHT, W. C., GILL, V. J., TUAZON, C. U., GELMANN, E. P., LANE, H. C., LONGFIELD, R., OVERTURF, G., et al. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-533 · Cited by 621
Self-citationZUGER, A., LOUIE, E., HOLZMAN, R. S., SIMBERKOFF, M. S., & RAHAL, J. J. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-2-234 · Cited by 522
Azole antifungal agents: Emphasis on new triazoles
Saag, M. S., & Dismukes, W. E. (1988) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.32.1.1 · Cited by 474
Self-citationDismukes, W. E., Cloud, G., Gallis, H. A., Kerkering, T. M., Medoff, G., Craven, P. C., Kaplowitz, L. G., Fisher, J. F., Gregg, C. R., Bowles, C. A., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708063170602 · Cited by 417
Self-citationCryptococcal Meningitis in Patients with AIDS
Dismukes, W. E. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/157.4.624 · Cited by 389
Self-citationLarsen, R. A., Leal, M. A. E., & Chan, L. S. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-3-183 · Cited by 357
Bozzette, S. A., Larsen, R. A., Chiu, J., Leal, M. A. E., Jacobsen, J., Rothman, P., Robinson, P., Gilbert, G., McCutchan, J. A., Tilles, J., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102283240902 · Cited by 301
Self-citationPerfect, J. R., Savani, D. V., & Durack, D. T. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.29.4.579 · Cited by 184
Stern, J. J., Hartman, B. J., Sharkey, P., Rowland, V., Squires, K. E., Murray, H. W., & Graybill, J. R. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)80081-0 · Cited by 158
Self-citationClark, R. A., Greer, D., Atkinson, W., Valainis, G. T., & Hyslop, N. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.5.768 · Cited by 156
Self-citationOverview: Treatment of Cryptococcal Meningitis
Sugar, A. M., Stem, J. J., & Dupont, B. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s338 · Cited by 73
Self-citationTreatment of cryptococcal meningitis in mice with fluconazole
de Fernandez, E. P., Patino, M. M., Graybill, J. R., & Tarbit, M. H. (1986) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/18.2.261 · Cited by 62
Fluconazole Therapy for Experimental Cryptococcosis and Candidiasis in the Rabbit
Perfect, J. R. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_3.s299 · Cited by 19
Cited by
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Self-citationCryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans
Mitchell, T. G., & Perfect, J. R. (1995) · Clinical Microbiology Reviews · doi:10.1128/cmr.8.4.515 · Cited by 1,213
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
“3 mg/kg) (median time to first negative CSF culture, 64 and 42 days, respectively) (227), higher fluconazole doses ($800 mg/day) have been studied as salvage therapy in HIV-infected patients who failed to respond to prior therapy for cryptococcal meningitis (19) and as primary therapy (115, 159).”
BackgroundPractice Guidelines for the Management of Cryptococcal Disease
Saag, M. S., Graybill, R. J., Larsen, R. A., Pappas, P. G., Perfect, J. R., Powderly, W. G., Sobel, J. D., Dismukes, W. E., & Mycoses Study Group Cryptococcal Subproject (2000) · Clinical Infectious Diseases · doi:10.1086/313757 · Cited by 1,105
Self-citationEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Metadata
- Authors
- Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K., Thompson, S. E., Sugar, A. M., Tuazon, C. U., Fisher, J. F., Hyslop, N., Jacobson, J. M., Hafner, R., & Dismukes, W. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1992-01-09
- Volume
- 326
- Issue
- 2
- Pages
- 83-89
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2317790888
- Cited by
- 631
- References
- 20
- FWCI
- 40.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.